Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBSZPF)

DTT Name	Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)
Synonyms	Siglec-15; SIGLEC15; CD33 antigen-like 3
Gene Name	SIGLEC15
DTT Type	Clinical trial target	[1]
BioChemical Class	Immunoglobulin
UniProt ID	SIG15_HUMAN
TTD ID	T85507
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MEKSIWLLACLAWVLPTGSFVRTKIDTTENLLNTEVHSSPAQRWSMQVPPEVSAEAGDAA VLPCTFTHPHRHYDGPLTAIWRAGEPYAGPQVFRCAAARGSELCQTALSLHGRFRLLGNP RRNDLSLRVERLALADDRRYFCRVEFAGDVHDRYESRHGVRLHVTAAPRIVNISVLPSPA HAFRALCTAEGEPPPALAWSGPALGNSLAAVRSPREGHGHLVTAELPALTHDGRYTCTAA NSLGRSEASVYLFRFHGASGASTVALLLGALGFKALLLLGVLAARAARRRPEHLDTPDTP PRSQAQESNYENLSQMNPRSPPATMCSP
Function	Binds sialylated glycoproteins.
Reactome Pathway	DAP12 interactions (R-HSA-2172127 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NC318	DMT6O2E	Non-small-cell lung cancer	2C25	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019 Apr;25(4):656-666.
2	Clinical pipeline report, company report or official report of NextCure.